Tag: AFMTELETHON
MEDESIS PHARMA receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD, its RNA interference treatment for Huntington’s disease – 07/20/2022 at 08:00
Montpellier, July 20, 2022 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for the administration of active ingredients in…